Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CNS Infections

A new herpes zoster subunit vaccine for older adults

A randomized placebo-controlled phase III trial of adjuvanted herpes zoster subunit vaccine has shown a substantial improvement in vaccine efficacy in adults aged ≥70 years compared with the currently used, live attenuated vaccine. The finding has profound implications for reducing illness burden, although the duration of vaccine protection needs further evaluation.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Cunningham, A. L. et al. Efficacy of herpes zoster subunit vaccine in adults 70 years of age or older. N. Engl. J. Med. 375, 1019–1032 (2016).

    CAS  Article  Google Scholar 

  2. 2

    Lal, H. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 372, 2087–2096 (2015).

    Article  Google Scholar 

  3. 3

    Cook, S. J. & Flaherty, D. K. Review of the persistence of herpes zoster vaccine efficacy in clinical trials. Clin. Ther. 37, 2388–2397 (2015).

    CAS  Article  Google Scholar 

  4. 4

    Oxman, M. N. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352, 2271–2284 (2005).

    CAS  Article  Google Scholar 

  5. 5

    Schmader, K. E. et al. Efficacy, safety and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin. Infect. Dis. 54, 922–928 (2012).

    Article  Google Scholar 

  6. 6

    Levin, M. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr. Opin. Immunol. 24, 494–500 (2012).

    CAS  Article  Google Scholar 

  7. 7

    Macaulay, R., Akbar, A. N. & Henson, S. M. The role of the T cell in age-related inflammation. Age (Dordr.) 35, 563–572 (2013).

    CAS  Article  Google Scholar 

  8. 8

    Hope-Simpson, R. E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med. 58, 9–20 (1965).

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9

    Forbes, H. J. et al. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients: a cohort study. Neurology 87, 94–102 (2016).

    CAS  Article  Google Scholar 

  10. 10

    Hobbelen, P. H. F., Stowe, J., Amirthalingam, G., Miller, L. & van Hoek, A.-J. The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J. Infect. 73, 241–253 (2016).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Judith Breuer.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Warren-Gash, C., Breuer, J. A new herpes zoster subunit vaccine for older adults. Nat Rev Neurol 12, 682–683 (2016). https://doi.org/10.1038/nrneurol.2016.168

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing